Skip to content
Screener

IDEAYA Biosciences, Inc. IDYA Q1 2026 earnings

Reported May 5, 2026 · Before market open

Revenue$6.6MBeat by $1.5M
EPS-$1.11Miss by $0.04
Revenue estimate$5.0M
EPS estimate-$1.07

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$6.8M
EPS estimate-$1.18

Financials

Q1 2026

Income statement

See full
Revenue$6.6M—
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.93B+104%
Enterprise value$2.8B+110%

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0×0.0×
Current ratio10.7×-3.2×

FAQ

When did IDEAYA Biosciences, Inc. report Q1 2026 earnings?
IDEAYA Biosciences, Inc. (IDYA) reported Q1 2026 earnings on May 5, 2026 before market open.
What were IDEAYA Biosciences, Inc.'s Q1 2026 revenue and EPS?
IDEAYA Biosciences, Inc. reported revenue of $6.6M and eps of $-1.11 for Q1 2026.
Did IDEAYA Biosciences, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $5.0M by $1.5M. EPS missed the consensus estimate of $-1.07 by $0.04.
How did IDEAYA Biosciences, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 35.4% from $-0.82.
Where can I find IDEAYA Biosciences, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-204944) and the 10-Q periodic report (0001193125-26-206357) directly on SEC EDGAR. The filing index links above go to sec.gov.